Pharmacy Benefit Management & Third-Party Administration (NAICS 524292): An Investor's Primer

1. Overview

Pharmacy benefit managers (PBMs) are the middlemen of the U.S. drug supply chain. They sit between drug makers, pharmacies, and the health plans or employers that pay for medicine — deciding which drugs a plan covers, negotiating the discounts, processing the claims, and often owning the mail-order and specialty pharmacies that fill the prescriptions. North American Industry Classification System (NAICS) code 524292 groups these PBMs together with the "other" third-party administrators (TPAs) that process claims and run the back office for insurance plans and pension funds without taking on the insurance risk themselves.[1]

Why it matters: this is one of the most concentrated, most politically exposed, and most cash-generative corners of U.S. health care. A handful of firms sit astride roughly half a trillion dollars in annual drug spending plus a large market in benefits administration, earning fees on volume they largely control.[6][7] The catch for anyone looking to invest is that almost all of the profit is buried inside giant, diversified health-care companies — there is no clean public "pure-play PBM" — and the entire fee model is under simultaneous attack from Congress, the states, and the Federal Trade Commission (FTC).

Public vs. private ways in. Public-market investors reach the economics mainly through the diversified insurers that own the big three PBMs — UnitedHealth Group, Cigna, and CVS Health — plus a few smaller listed benefits- and claims-administration firms. Private-market investors have a richer menu: the fast-growing "transparent" PBM challengers (Capital Rx/Judi Health, SmithRx, Navitus), the Blue-Cross-owned Prime Therapeutics, independent PBMs, and private-equity-backed benefits administrators such as Personify Health and Sedgwick are all held privately or inside other operating companies. The key distinction throughout is between the drug dollars that merely pass through an administrator and the narrower service revenue that actually produces profit.

2. What it is and how it's structured

Two businesses under one code. NAICS 524292 covers establishments primarily engaged in (a) pharmacy benefit management — administering prescription-drug plans, building formularies (the covered-drug lists), negotiating rebates and pharmacy prices, and processing pharmacy claims; and (b) other third-party administration — processing claims and providing back-office administration for insurance carriers, self-insured employer plans, unions, and pension/welfare funds, without bearing insurance risk.[1] The common thread is that these firms are paid to administer other people's money and benefits, not to underwrite risk or to manufacture or dispense product.

The basic PBM flow:

• A health plan, employer, union, government program, or self-insured fund hires the PBM.
• The PBM negotiates with drug manufacturers, often through a group purchasing organization (GPO).
• It contracts with pharmacies, processes claims, manages formularies, and applies utilization controls (such as prior authorization).
• The sponsor pays the drug costs plus administrative fees, under either a "pass-through" or a "spread-pricing" contract (defined in Section 5).

TPAs do parallel administrative work for medical, dental, disability, workers'-compensation, flexible-spending, and retirement plans. Some compete on technology; others on local service, claims expertise, or union and government-plan relationships.

What it explicitly excludes (and the adjacent codes where that activity lives):

• Insurance underwriting — the carriers that actually bear risk: direct health/medical carriers (524114), life carriers (524113), reinsurers (524130).
• Claims adjusting — the sibling code 524291 (investigating and appraising claims) is separate from claims administration; other insurance-related advisory and actuarial services sit in 524298.
• Retail and mail-order dispensing — the pharmacies that hand over the pills are in Pharmacies & Drug Retailers (456110/446110); drug wholesalers are in 424210.
• The funds themselves — pension funds (525110) and health & welfare funds (525120) are the pools of money; 524292 firms only administer them.
• Insurance brokers and agencies (524210), portfolio management, and human-resources consulting.

Ownership mix. The center of gravity is a small number of very large, vertically integrated corporations. The three dominant PBMs are each a segment of a health-care giant — Caremark inside CVS Health, Express Scripts inside Cigna's Evernorth unit, and Optum Rx inside UnitedHealth Group — and each parent also owns insurers, pharmacies, and rebate-negotiating (GPO) entities.[6][17] Below them sit a Blue-Cross-plan-owned PBM (Prime Therapeutics)[34], large independent private PBMs (MedImpact)[37], venture- and payer-backed transparent challengers, and — on the TPA side — a long tail of privately held or private-equity-owned claims administrators (for example, Personify Health, which houses HealthComp's TPA business and is majority-owned by New Mountain Capital).[40] Federal statistics count 2,480 firms operating 6,151 establishments in this code.[2][3]

3. How big it is

Our ground-truth federal figures for NAICS 524292 blend the 2022 Economic Census with 2023 County Business Patterns (CBP); these are different vintages, not one year's financial statement.

CR4 is the share of industry receipts held by the four largest firms; the HHI is the sum of squared firm market shares, where higher means more concentrated. Federal profit, margin, covered lives, claims volume, and valuation multiples are not collected for this code — we do not invent them here.

Two undercount/mismatch caveats — both matter here.

1. The code likely understates the industry's true activity. The dominant PBMs are reported inside their parents' primary industry (insurance carriers), not under 524292. For scale: in 2024 the three big PBM/health-services segments alone reported roughly $187 billion (CVS Health Services), ~$198 billion (Cigna's Evernorth), and ~$133 billion (UnitedHealth's Optum Rx) in segment revenue — over $500 billion combined, well above the entire Census tally for the code.[10][11][12] Read the federal receipts number as a floor, not a full measure.
2. Whatever receipts are captured are not clean "service revenue." Reported receipts can include drug costs passed through to clients, so the figure is not a measure of U.S. prescription-drug spending, nor of PBM profit. Separately, CBP counts only employer establishments with paid staff — it excludes nonemployers and most government administrative work — so very small operators are undercounted too.[4]

A concentration caveat. The blended HHI of 1,633.5 looks only "moderately concentrated" (the U.S. Department of Justice treats 1,500–2,500 as moderate) — but that number mixes a few enormous PBMs with thousands of small TPAs. Inside the PBM sub-segment alone, the FTC found the three largest PBMs processed nearly 80% of the ~6.6 billion U.S. prescriptions dispensed in 2023, and the six largest processed more than 90% — far more concentrated than the blended index suggests.[8]

4. The investable universe

There is no pure-play public PBM stock. Every major PBM is a segment inside a diversified, publicly traded health-care company; buying the parent means buying the insurance and care-delivery businesses alongside the PBM.

Public companies (parent-level; scale = full-company or segment revenue as noted):

Major private / non-public owners:

• Prime Therapeutics — owned by roughly 19 Blue Cross Blue Shield plans; ~38 million members and hundreds of millions of claims.[34][7]
• MedImpact — the largest fully independent, privately held PBM (recently acquired Sav-Rx).[37]
• Navitus Health Solutions — owned by SSM Health and Costco Wholesale; ~18M members; transparent/pass-through model.[35][36]
• Capital Rx / Judi Health — venture-backed transparent PBM; raised a $400M round (Sept 2025, incl. Wellington and General Catalyst) and rebranded as it expands into medical-claims administration.[38]
• SmithRx — venture-backed (Venrock, Founders Fund) transparent PBM.[35]
• Mark Cuban Cost Plus Drug Company — a public-benefit corporation using a "cost plus 15%" model to route around traditional PBM economics.[39]
• Personify Health (New Mountain Capital), Sedgwick, Meritain (CVS/Aetna), UMR (UnitedHealth), Helmsman (Liberty Mutual), Allied Benefit Systems — large private or captive claims/benefits TPAs.[40]

The practical takeaway: public investors get diversified exposure (insurer + PBM + pharmacy) via UNH/CI/CVS, or more targeted TPA exposure via ALIT/CRVL; the disruptor upside — the transparent-PBM story — is almost entirely a private-market bet today.

5. How the money works

PBM and TPA owners make money on fees and volume, not on underwriting risk. The metrics that matter are prescription-claim volume, "gross-to-net" drug economics, rebate retention, per-member-per-month (PMPM) fees, generic/specialty mix, covered lives, and client-retention rates — not the rate base, occupancy, or reserve metrics of other financial industries.

PBMs — the main revenue streams:

1. Administrative / service fees — flat per-claim or PMPM fees charged to plan sponsors.[18]
2. Manufacturer rebates — retrospective payments drug makers pay for preferred formulary placement. Gross brand-drug rebates and discounts reached roughly $334 billion in 2023; PBMs pass most through to plans but retain a slice, and because rebates are typically a percentage of a drug's list price, the model can reward higher list prices.[19]
3. Spread pricing — charging the health plan more for a drug than the PBM reimburses the pharmacy, and keeping the difference. The Centers for Medicare & Medicaid Services (CMS) defines spread pricing precisely this way and, for certain plans, requires PBMs to report rebates, discounts, pass-through amounts, and spread — though those filings are not publicly released.[24]
4. Owned pharmacies — the big PBMs run their own mail-order and specialty pharmacies and capture the dispensing margin; specialty drugs (nearly half of some PBMs' managed spend) are the profit engine.[7][18]
5. GPO / rebate-aggregation and clinical/data fees — often booked through separate (sometimes offshore) group-purchasing entities.

Per-script margins are thin, but the volume is colossal, so small percentages compound into large absolute profits. The strategic shift now underway is toward "transparent" or pass-through contracts that hand 100% of rebates and true drug cost to the client and charge only a flat fee — compressing the spread-and-rebate economics the incumbents were built on.[35]

TPAs — asset-light recurring fees: claims administrators earn PMPM administrative fees, plus implementation, transaction, and technology revenue, from self-insured employers and pension/welfare funds — while the employer (not the TPA) funds the actual claims. It is a low-capital, recurring-revenue model closer to software-enabled business services than to insurance; its economics turn on client retention, PMPM pricing, and scale. The Employee Retirement Income Security Act of 1974 (ERISA) preemption is what makes self-funding — and therefore the TPA market — so large.[23]

The investor's lens: focus on true service revenue, contribution margin, client retention, generic/specialty mix, rebate pass-through, claims accuracy, cash conversion, and working capital. Gross prescription volume alone can be misleading, and rising drug spending does not automatically lift margins — sponsors can compete the savings away.

6. What drives demand

• Total drug spending and price complexity. CMS reported U.S. prescription-drug spending of $467.0 billion in 2024, up 7.9%, and projects retail prescription-drug spending to grow about 5.7% a year from 2025 through 2034 — more scripts and higher-priced brands mean more volume and more rebate dollars flowing through PBMs.[20]
• Specialty and GLP-1 drugs — the biggest single tailwind. Specialty drugs, biologics, gene therapies, and glucagon-like peptide-1 (GLP-1) medicines raise the value of formulary and utilization management.[9] GLP-1 medicines (Ozempic, Wegovy, Mounjaro, Zepbound) posted roughly $132 billion in 2025 sales, up ~34% year over year, and obesity-drug spending alone could reach ~$60 billion by 2029; formulary decisions on these drugs are now a central PBM battleground.[21][22]
• Employer self-funding. As more employers self-insure to escape state insurance mandates, demand for both PBMs and claims TPAs rises.[23]
• Government-program enrollment. Medicare Part D and Medicaid managed care push large blocks of lives (and drug spend) through PBMs; the loss or win of a single contract can move share sharply.[6]
• Aging, chronic disease, and administrative complexity — plus rising prior-authorization, data, and cybersecurity requirements, and demand for transparent, real-time benefit information — provide structural, long-run volume growth.

7. Regulation

This is a heavily and increasingly regulated industry, on two distinct tracks.

PBMs. After decades of light federal oversight, scrutiny has intensified sharply:

• The FTC's 2024 interim report found the top six PBMs control more than 90% of the market and flagged vertical integration and self-dealing; a 2025 second interim report followed on specialty-drug and pricing practices.[8][9]
• In September 2024 the FTC sued CVS Caremark, Express Scripts, and Optum Rx over insulin rebate practices.[30] By 2026 the FTC had reached settlements with Express Scripts (projected to cut patient insulin costs by up to $7 billion over 10 years) and CVS/Caremark, with the Optum matter still being considered for a proposed consent agreement as of mid-2026.[31][32]
• States have moved aggressively: the National Association of Insurance Commissioners (NAIC) reports all 50 states enacted at least one PBM law between 2017 and 2023, and one tracker counts roughly 186 PBM-related laws from 2017–2024 — covering licensing, spread pricing, pharmacy reimbursement, transparency, and "delinking" (barring PBM pay from being tied to a drug's price; Colorado's takes effect 2027, with California and others following).[25][26]
• The Supreme Court has affirmed state authority here: in Rutledge v. Pharmaceutical Care Management Association (2020), it held that ERISA did not preempt Arkansas's PBM rate-regulation law — clearing the way for the wave of state statutes.[28]
• Medicare Part D. CMS regulates Part D drug-plan sponsors and collects PBM pricing and rebate data (not publicly released); since 2024, pharmacy price concessions must be reflected in the drug's negotiated price at the point of sale — lowering patient cost-sharing while removing a former PBM/pharmacy revenue lever.[24]
• Federal bills advanced but not yet law include the PBM Reform Act of 2025 (H.R. 4317) and the Crapo–Wyden PBM Price Transparency and Accountability Act (S. 3345), which would ban Medicaid spread pricing, force full rebate pass-through, and delink PBM pay in Medicare Part D. Part D itself is already being reshaped by the Inflation Reduction Act's Medicare price negotiation and $2,000 out-of-pocket cap.[27]

TPAs and data. Self-insured health plans fall under ERISA, enforced by the U.S. Department of Labor (DOL), which imposes fiduciary duties; ERISA preemption limits how far states can reach self-funded plans.[23] In 2026 the DOL proposed a new PBM fee-disclosure rule (comment period later extended; still proposed, not final).[29][42] State insurance departments license and bond health-plan TPAs unevenly. Across both tracks, the Health Insurance Portability and Accountability Act (HIPAA) imposes privacy and security duties on plans and their business associates handling protected health information.[33]

8. Competitive dynamics and consolidation

Two forces define competition here: integration and insurgency.

Vertical and horizontal integration. Each of the big three PBMs is fused into an insurer, owns its own pharmacies, and runs GPO/rebate entities — so a single corporate parent can capture margin at the plan, the PBM, and the pharmacy at once. Horizontal consolidation left the top three processing nearly 80% of claims and the top six over 90%.[8] Scale confers bargaining power over manufacturers and pharmacies, data and compliance advantages, specialty-pharmacy capability, and high switching costs — but the same vertical model is exactly what the FTC and legislators have targeted for self-preferencing and conflicts of interest.

The transparent-PBM insurgency. A coalition of smaller, pass-through PBMs — Navitus, SmithRx, Capital Rx/Judi Health, and others, several organized under industry groups pushing transparency — is winning employers who want flat-fee, full-rebate contracts, and pointing to the incumbents' opaque spread-and-rebate model as the problem.[35] Notably, the incumbents are responding on their own terms: Cigna's Evernorth and UnitedHealth's Optum Rx have announced models meant to reduce reliance on opaque rebate and spread economics — company commitments, not guarantees of industry-wide reform.[11][41] The open question is whether challengers can scale against incumbents that still control much of the underlying pharmacy-network contracting — a forward-looking judgment, not a settled outcome. The TPA side, by contrast, remains far more fragmented, where regional service, union relationships, and flexible technology still win business.

9. Risks

• Regulatory/legislative model risk (the dominant one). Delinking, mandated rebate pass-through, and spread-pricing bans would strike directly at the PBMs' core profit streams. If federal delinking passes, the traditional economics change materially — a live threat, not a tail risk.[26][27]
• Antitrust, litigation, and enforcement. The FTC insulin actions, ERISA fiduciary-breach suits against plan sponsors and administrators, and antitrust rulings create ongoing legal and settlement exposure for the consolidated, vertically integrated operators.[8][31]
• Client repricing / margin compression. Large employers and health plans can rebid contracts and demand full pass-through, eroding spread and rebate retention even without new laws.[35]
• Specialty-drug and GLP-1 cost shock. Explosive high-cost-drug demand strains plan budgets and forces contentious formulary exclusions, pressuring both PBM economics and client relationships, and adding pricing/guarantee risk.[21][22]
• Customer concentration. Because a handful of mega-contracts drive share, losing one can swing volumes sharply.[6]
• Cybersecurity and privacy. Claims and prescription systems hold highly sensitive health data; a breach carries legal and reputational cost.[33]
• Accounting opacity. Gross drug receipts can obscure the true (much smaller) service margin and working-capital needs.
• Private-market leverage. PE-backed TPA/PBM platforms may carry debt and face refinancing or integration risk.
• Reputational/political risk. PBMs are a bipartisan target; policy risk can arrive faster than in most industries.

10. How to invest and the outlook

Public routes. The only listed way into PBM economics is through the diversified parents — UnitedHealth Group (UNH), Cigna (CI), CVS Health (CVS), and more peripherally Elevance Health (ELV) and Humana (HUM). Treat these as bets on integrated managed care, not standalone PBM plays: the PBM is a large, cash-generative engine, but its policy risk is now a first-order swing factor for the whole company. For the benefits/claims-TPA slice, the more targeted listed exposures are Alight (ALIT) and CorVel (CRVL), with Crawford & Company (CRD.A/CRD.B) as the closest pure claims-administration play and broker Arthur J. Gallagher (AJG) owning a large claims TPA (Gallagher Bassett). When you analyze any of these, separate the relevant PBM/TPA segment from the parent's insurance and pharmacy businesses, and ask: what share of revenue is true service revenue versus pass-through drug cost? How are rebates, spread, and affiliated-pharmacy arrangements disclosed? Does the company bear medical, drug-cost, or underwriting risk? What are renewal and retention economics? How exposed is it to state-by-state compliance and FTC settlements? (Valuation, yield, and multiples belong in company-level analysis.)

Private routes. The more differentiated opportunity is private: the transparent-PBM challengers (Capital Rx/Judi Health, SmithRx, Navitus), the Blue-owned Prime Therapeutics, independent MedImpact, and PE-backed benefits administrators such as Personify Health and Sedgwick. Venture and growth capital have flowed into the transparent-PBM thesis (Capital Rx's $400M round; SmithRx's Venrock-led financings) — a wager that regulation and employer demand will shift share away from the incumbents.[35][38] Private diligence should emphasize recurring contracts, renewal rates, customer concentration, claims accuracy, audit rights, data security, technology scalability, licensing, and debt service. (The SBA's $45.5M receipts threshold is a government-contracting definition, not a valuation category.)

Near-term drivers to watch (forward-looking):

1. Whether federal delinking / rebate-reform legislation actually passes — the single biggest binary for incumbent economics.[27]
2. The pace of employer defection to transparent, pass-through models — and how convincingly incumbents' own "transparent" models blunt it.[35][41]
3. GLP-1/obesity-drug spend trajectory and how PBMs price and gate it.[21][22]
4. Follow-through on the FTC settlements and any new enforcement, including the pending Optum matter.[31][32]
5. Large contract wins/losses that reshuffle the ~80%-concentrated top of the market.[6]

Bottom line: a quietly enormous, highly concentrated, fee-driven industry whose incumbents throw off large cash flows but face a rare convergence of regulatory, legislative, litigation, and competitive pressure aimed at the exact mechanisms that make them profitable. Demand for prescription-benefit and benefit administration should stay durable, but the most attractive economics are likely to migrate toward transparent fee-based models, high-retention TPAs, and cost-lowering technology. The public opportunity is diversified and defensive; the disruptive upside is, for now, mostly private.

---

Sources

1. U.S. Census Bureau. "NAICS 524292 — Pharmacy Benefit Management and Other Third Party Administration of Insurance and Pension Funds," 2022. https://www.census.gov/naics/?details=524292&input=524292&year=2022
2. U.S. Census Bureau. 2022 Economic Census — receipts, firm counts, and concentration ratios (CR4/CR8/CR20/CR50, HHI), NAICS 524292. https://data.census.gov/table/ECNSIZE2022.EC2200SIZECONCEN?q=EC2200SIZECONCEN
3. U.S. Census Bureau. County Business Patterns 2023 — establishments, employment, and payroll, NAICS 524292. https://www.census.gov/data/datasets/2023/econ/cbp/2023-cbp.html
4. U.S. Census Bureau. "County Business Patterns Methodology" (coverage of employer establishments). https://www.census.gov/programs-surveys/cbp/technical-documentation/methodology.html
5. U.S. Small Business Administration. "Table of Size Standards" / 13 CFR §121.201 (NAICS 524292: $45.5M). https://www.govinfo.gov/content/pkg/CFR-2025-title13-vol1/pdf/CFR-2025-title13-vol1-sec121-201.pdf
6. Fein, Adam J. "The Top Pharmacy Benefit Managers of 2024: Market Share and Key Industry Developments." Drug Channels, 2025. https://www.drugchannels.net/2025/06/the-top-pharmacy-benefit-managers-of.html
7. Fein, Adam J. "The Top Pharmacy Benefit Managers of 2025: Market Share and Key Industry Developments." Drug Channels, 2026. https://www.drugchannels.net/2026/03/the-top-pharmacy-benefit-managers-of.html
8. U.S. Federal Trade Commission. "Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs" (interim staff report). 2024. https://www.ftc.gov/news-events/news/press-releases/2024/07/ftc-releases-interim-staff-report-prescription-drug-middlemen
9. U.S. Federal Trade Commission. "FTC Releases Second Interim Staff Report on Prescription Drug Middlemen." 2025. https://www.ftc.gov/news-events/news/press-releases/2025/01/ftc-releases-second-interim-staff-report-prescription-drug-middlemen
10. Managed Healthcare Executive. "CVS's Health Services Revenue Grew to $186.8 Billion." 2025. https://www.managedhealthcareexecutive.com/view/cvs-s-health-services-revenue-grew-to-186-8-billion
11. The Cigna Group. Form 10-K (Evernorth / Express Scripts segment). U.S. SEC. https://www.sec.gov/Archives/edgar/data/1739940/000173994026000006/ci-20251231.htm
12. UnitedHealth Group. Form 10-K (Optum Rx segment). U.S. SEC. https://www.unitedhealthgroup.com/content/dam/UHG/PDF/investors/2025/UNH-Q4-2025-Form-10-K.pdf
13. CVS Health. Form 10-K (Caremark / Health Services segment). U.S. SEC. https://www.sec.gov/Archives/edgar/data/64803/000006480326000010/cvs-20251231.htm
14. Elevance Health. Form 10-K (CarelonRx). U.S. SEC. https://www.sec.gov/Archives/edgar/data/1156039/000115603926000013/elv-20251231.htm
15. Alight. Form 10-K (benefits administration). U.S. SEC. https://www.sec.gov/Archives/edgar/data/1809104/000162828026011108/alit-20251231.htm
16. CorVel. Form 10-K (claims management / TPA). U.S. SEC. https://www.sec.gov/Archives/edgar/data/874866/000095017025076999/crvl-20250331.htm
17. Center for American Progress. "5 Things To Know About Pharmacy Benefit Managers." 2024. https://www.americanprogress.org/article/5-things-to-know-about-pharmacy-benefit-managers/
18. AffirmedRx. "Three Ways PBMs Make Money: Rebates, Admin Fees and Spread." 2024. https://affirmedrx.com/how-pbms-make-money/
19. Commonwealth Fund. "What Pharmacy Benefit Managers Do, and How They Contribute to Drug Spending." 2025. https://www.commonwealthfund.org/publications/explainer/2025/mar/what-pharmacy-benefit-managers-do-how-they-contribute-drug-spending
20. Centers for Medicare & Medicaid Services. "National Health Expenditure Fact Sheet." 2026. https://www.cms.gov/data-research/statistics-trends-and-reports/national-health-expenditure-data/nhe-fact-sheet
21. American Medical Association. "Spending on GLP-1s has grown dramatically. Here are the details." 2025. https://www.ama-assn.org/public-health/behavioral-health/spending-glp-1s-has-grown-dramatically-here-are-details
22. Managed Healthcare Executive. "IQVIA Predicts Spending on Obesity Drugs Could Reach $60 Billion by 2029." 2025. https://www.managedhealthcareexecutive.com/view/iqvia-predicts-spending-on-obesity-drugs-could-reach-60-billion-by-2029-pbmi-2025
23. Arkansas Center for Health Improvement / U.S. Department of Labor. "The Role of Third-Party Administrators in Health Insurance Coverage"; "Understanding Your Fiduciary Responsibilities Under a Group Health Plan." 2024. https://achi.net/publications/the-role-of-third-party-administrators-in-health-insurance-coverage/
24. Centers for Medicare & Medicaid Services. "Drug Data, Pricing & Rebate Review" (spread-pricing definition; reporting). 2025. https://www.cms.gov/marketplace-private-insurance/health-plans-issuers/drug-data-pricing-rebate-review
25. National Association of Insurance Commissioners. "Pharmacy Benefit Managers." 2025. https://content.naic.org/insurance-topics/pharmacy-benefit-managers
26. MultiState. "Pharmacy Benefit Manager (PBM) Legislation Tackled Ownership Restrictions, Transparency, and More in 2025." 2026. https://www.multistate.us/insider/2026/1/27/pharmacy-benefit-manager-pbm-legislation-tackled-ownership-restrictions-transparency-and-more-in-2025
27. AMCP. "Federal Update: Senate Introduces Comprehensive PBM Reform Legislation." 2025. https://www.amcp.org/letters-statements-analysis/federal-update-senate-introduces-comprehensive-pbm-reform-legislation
28. Supreme Court of the United States. Rutledge v. Pharmaceutical Care Management Association. 2020. https://www.supremecourt.gov/opinions/20pdf/18-540_m64o.pdf
29. U.S. Department of Labor. "Proposed Pharmacy Benefit Manager Fee Disclosure Rule." 2026. https://www.dol.gov/agencies/ebsa/about-ebsa/our-activities/resource-center/fact-sheets/proposed-pharmacy-benefit-manager-fee-disclosure-rule
30. NPR. "FTC sues pharmacy benefit managers for inflating price of insulin." 2024. https://www.npr.org/2024/09/21/nx-s1-5121886/insulin-ftc-lawsuit-pharmacy-benefit-manager
31. U.S. Federal Trade Commission. "FTC Secures Major Settlement with Caremark, Resolving Antitrust Case Against Second Drug Middleman." 2026. https://www.ftc.gov/news-events/news/press-releases/2026/07/ftc-secures-major-settlement-caremark-resolving-antitrust-case-against-second-drug-middleman
32. Healthcare Dive. "CVS, FTC reach proposed settlement in insulin pricing case." 2026. https://www.healthcaredive.com/news/cvs-caremark-ftc-proposed-settlement-insulin-lawsuit/815581/
33. U.S. Department of Health and Human Services. "HIPAA — Covered Entities and Business Associates." 2024. https://www.hhs.gov/hipaa/for-professionals/covered-entities/index.html
34. Prime Therapeutics. "Prime Therapeutics Introduces a Bold New Brand and Vision." 2024. https://www.primetherapeutics.com/w/prime-therapeutics-introduces-a-bold-new-brand-and-vision-to-reimagine-pharmacy-solutions
35. Modern Healthcare. "Navitus Health, SmithRx aim to grow PBM market share in 2025." 2025. https://www.modernhealthcare.com/insurance/navitus-health-solutions-smithrx-capital-rx-pbm-market-2025/
36. Navitus Health Solutions. "Business Portfolio" (SSM Health / Costco ownership). 2026. https://navitus.com/our-company/business-portfolio/
37. MedImpact. "MedImpact Completes Acquisition of Sav-Rx." 2026. https://www.medimpact.com/clients/resources/press-releases/medimpact-completes-acquisition-sav-rx
38. PR Newswire. "Capital Rx Announces Funding Round of $400M… Rebrands as 'Judi Health.'" 2025. https://www.prnewswire.com/news-releases/capital-rx-announces-funding-round-of-400m-to-accelerate-ai-powered-health-benefits-platform-rebrands-as-judi-health-to-reflect-expansion-beyond-pharmacy-302563763.html
39. Mark Cuban Cost Plus Drug Company. Company website. 2025. https://www.markcubancostplusdrugcompany.com/
40. Personify Health. "Virgin Pulse and HealthComp Introduce Combined Company as Personify Health" (New Mountain Capital ownership). 2023. https://personifyhealth.com/press/virgin-pulse-and-healthcomp-introduce-combined-company-as-personify-health/
41. UnitedHealth Group. "Optum Rx Introduces Industry-First Transparent Pharmacy Care Model." 2026. https://www.unitedhealthgroup.com/newsroom/2026/2026-05-11-optum-rx-introduces-industry-first-transparent-pharmacy-care-model.html
42. U.S. Department of Labor, Employee Benefits Security Administration. "Comment-Period Extension — Proposed PBM Fee Disclosure Rule" (EBSA news release). 2026. https://www.dol.gov/newsroom/releases/ebsa/ebsa20260227